Report : North America Small Molecule Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, Central Nervous System, Cardiovascular, Respiratory, Orthopedics, Immunology, Rare Diseases, and Other Therapeutic Areas); Process/Phase (Target Discovery, Target Validation, Lead Generation and Refinement, and Preclinical Development), and Country

Rare diseases segment by therapeutic type is estimated to lead the market growth during the forecast period

 

According to a new market research study of “North America Small Molecule Drug Delivery Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic Type and Process/Phase, ”the North America Small molecule drug delivery is projected to reach US$  26,458.48 million by 2027 from US$  12,791.35  million in 2019. The market is estimated to grow at CAGR of 9.8% from 2020 to 2027. The report highlights trends prevailing in the North America small molecule drug delivery market and the factors driving market along with those that act as hindrances.

 

Based on therapeutic type, the North America small molecule drug delivery market is further segmented into oncology, central nervous system, cardiovascular, respiratory, orthopedics, immunology, rare diseases, and other therapeutic areas. The oncology segment held the larger share of the market in 2019, however, rare diseases is anticipated to register the highest CAGR in the market during the forecast period. Many pharmaceutical companies are working in this space and trying to bring novel approaches in the market for the treatment of rare diseases. For instance, Ultragenyx, a biopharmaceutical company is engaged in the development of novel products for the treatment of rare and ultra-rare diseases. The company was founded in 2010 and have a diverse portfolio of candidates with the potential to address diseases. Its UX007 candidate is a small molecule for Long-Chain Fatty Acid Oxidation Disorders (FAOD). It is currently in phase 2 of clinical trials.

 

North America small molecule drug delivery market is expected to grow owing to factors such growing numbers of small molecules drug approvals is likely to propel the growth of the market. However, high cost associated with drug development is the major factor hindering the market growth..

 

Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., and Gilead Sciences, Inc.are among the leading companies operating in the North America small molecule drug delivery market.

 

North America Small Molecule Drug Delivery Market, By Country, 2019 (% share)

North America Small Molecule Drug Delivery Market, By Country, 2019 (% share)

 

The report segments in North America small molecule drug delivery market as follows:

 

By Therapeutic Area

  • Oncology
  • Central Nervous System
  • Cardiovascular
  • Respiratory
  • Orthopedics
  • Immunology
  • Rare Diseases
  • Other Therapeutic Areas

By Process/Phase

  • Target Discovery
  • Target Validation
  • Lead Generation and Refinement
  • Preclinical Development

By Country

  • North America
    • US
    • Canada
    • Mexico
Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com    

Download Free PDF Brochure